In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Best Vascular Inc./ Novoste

Division of Best Medical International Inc.
www.bestvascular.com

Latest From Best Vascular Inc./ Novoste

The Lure of Late-Stage Device Investing

In 2006, the number of late-stage private equity deals in the medical device sector is up significantly from 2005. At the IN3 East medtech conference in October, a lively panel of venture capital investors from Galen Partners, 3i, Matignon Technologies and OrbiMed Advisors discussed why this is so, and the risks, benefits and models for late-stage investing.
Medical Device Business Strategies

Cardio3: Moving from Science Project to Business Model in Stem Cells

Cardiac stem cell therapy for regenerating diseased heart tissue has been long on promise but short on delivery. A Belgian incubator and start-up hope to finally bring this treatment to market.
BioPharmaceutical Business Strategies

Devices for Age-Related Macular Degeneration

The recent FDA approval of The Pfizer/Eyetech drug Macugen, which is expected to yield $350 million in its first year on the market, has focused attention on the opportunity in age-related macular degeneration. But AMD isn't only a pharmaceutical opportunity. AMD is a disease of the retina, in the back of the eye, and that presents delivery problems that devices can solve. Device companies are developing drug delivery implants, device therapies, borrowed from the cardiovascular industry, and new photodynamic therapies that aim to rival Visudyne, QLT's laser-activated drug for wet AMD.
BioPharmaceutical Combination Products

Conor: An Outsider Delivers Drug-Stents' Next Generation

Drug-eluting stents (DES), now approved in the US, will be the first blockbuster combination drug/device product to hit the market. First generation DES products use a stent design that remains basically unchanged from bare metal stents, bascially adding thin layers of drug and polymer coatings. Conor Medsystems is developing a stent that is specifically designed as a drug delivery vehicle, while still embodying the attributes required of a standard stent. Conor's stent is based on work done by an engineer with no expereince in the medical products industry, based on technology developed in other areas, bringing a fresh look to the future of combining drugs and stents that may extend to therapeutic applications beyond treating only cardiovascular disease.
Medical Device Strategy
See All

Company Information

  • Industry
  • Medical Devices
  • Therapeutic Areas
  • Cardiovascular
  • Alias(es)
  • Novoste Corp.
  • NOVT Corp.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Best Medical International Inc.
  • Senior Management
  • Alfred J Novak, Pres. & CEO
    Subhash C Sarda, VP, Fin. & CFO
    Andrew M Green, VP, Reg. & Clinical Affairs
    Cheryl R Johnson, VP, Bus. Dev.
  • Contact Info
  • Best Vascular Inc./ Novoste
    Phone: (770) 717-0904
    4350 International Blvd.
    Suite A
    Norcross, GA 30093
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register